Madrigal Pharmaceuticals, Inc. (0JXI.L)
LSE · USD
$442.00 (-0.57%) as of
Key statistics
- EPS (TTM)
- -14.65
- 52-week range
- 122.87 – 449.00
- Beta
- -1.05
- Revenue (TTM)
- 1.28B
- Profit margin
- -25.32%
- Volume
- 6.00
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Headquarters
- West Conshohocken, PA, United States
- Employees
- 915
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.